Back to top
more

Marinus Pharmaceuticals (MRNS)

(Delayed Data from NSDQ)

$0.33 USD

0.33
2,281,602

+0.03 (8.25%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $0.33 0.00 (0.64%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Marinus Pharmaceuticals (MRNS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?

by Zacks Equity Research

Actinium (ATNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -13.98% and 20.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 100% and 11.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last?

by Zacks Equity Research

ChemoCentryx (CCXI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Marinus (MRNS) to Sell Rare Disease PRV to Novo Nordisk

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of -13.04% and 5.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Marinus Pharmaceuticals (MRNS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder

by Zacks Equity Research

The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.

Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.94% and 42.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Sigilon Therapeutics, Inc. (SGTX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of -19.57% and 47.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50% and 37.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis (ORGO) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of 412.50% and 3.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0% and 13.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 30.26% and 335.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.41% and -25.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for July 16th

by Zacks Equity Research

JAZZ, MRNS, TWO, NCMI, and CRON have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2021

New Strong Sell Stocks for July 9th

by Zacks Equity Research

BEST, JRSH, MRNS, MFGP and SABR have been added to the Zacks Rank #5 (Strong Sell) List on July 9, 2021.

New Strong Sell Stocks for June 21st

by Zacks Equity Research

ASTE, CMTL, EBMT, MRNS and WRE have been added to the Zacks Rank #5 (Strong Sell) List on June 21, 2021.

New Strong Sell Stocks for June 4th

by Zacks Equity Research

ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -60.87% and -30.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -5.77% and -12.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study

by Zacks Equity Research

Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA filing.